| Cambodia | Ethiopia | Kenya | Lao PDR | Malawi | Pakistan | Philippines | Uganda | Tanzania | Vietnam | Zambia |
---|---|---|---|---|---|---|---|---|---|---|---|
Population aged 15 and above, 2019, million | 11.4 | 66.9 | 32 | 4.9 | 10.5 | 140.6 | 75.2 | 23.7 | 32.6 | 74.1 | 9.9 |
Prevalence survey | |||||||||||
Survey year | 2011 | 2010–2011 | 2016 | 2010–2011 | 2013 | 2010–2011 | 2016 | 2014–2015 | 2012 | 2017–2018 | 2013–2014 |
Prevalence in the survey year, per 100,000a | 839 (748–933) | 236 (193–281) | 478 (425–532) | 604 (528–683) | 418 (348–491) | 325 (291–360) | 998 (908–1090) | 395 (335–456) | 305 (258–355) | 358 (311–406) | 575 (508–644) |
WHO data/estimates | |||||||||||
Case notification, 2019, per 100,000 | 247 (244–250) | 150 (149–150) | 238 (236–240) | 138 (135–142) | 146 (144–148) | 201 (200–202) | 488 (486–489) | 238 (236–240) | 212 (210–213) | 136 (135–137) | 340 (336–343) |
Case-detection ratio | 57 (40.0–88) | 69 (51.0–98) | 63 (43.0–100) | 57 (40.0–89) | 56 (35.0–110) | 64 (48.0–90) | 63 (40.0–110) | 65 (43.0–110) | 53 (30.0–110) | 57 (40.0–90) | 58 (41.0–90) |
Incidence rate in 2019, per 100,000 | 387 (220–546) | 208 (133–283) | 385 (194–572) | 206 (120–288) | 218 (85–361) | 351 (225–478) | 705 (310–1102) | 304 (135–473) | 356 (98–617) | 219 (127–312) | 534 (302–766) |
Model estimates: All TB regardless of symptomatic or not | |||||||||||
Duration by P:N ratio, monthb | 28.9 (25.8–32.3) | 10.2 (8.4–12.3) | 25.1 (22.5–28.0) | 109.4 (95.1–125.6) | 29.7 (25.1–34.9) | 17.8 (15.9–19.9) | 33.3 (30.5–36.4) | 24.5 (21.0–28.5) | 20.8 (17.7–24.2) | 33.0 (28.6–37.3) | 16.0 (14.2–18.0) |
Time bacteriologically positive, month | 22.0 (18.9–25.8) | 9.0 (7.5–10.8) | 18.3 (16.1–21.0) | 36.1 (29.9–45.3) | 21.8 (18.4–25.9) | 13.1 (11.5–14.8) | 22.3 (19.6–25.6) | 19.1 (16.4–22.2) | 16.2 (14.0–18.8) | 20.7 (17.8–24.5) | 13.4 (11.8–15.2) |
Case-detection ratioc | 67% (56–79%) | 87% (80–94%) | 69% (60–79%) | 24% (19–31%) | 63% (53–74%) | 76% (68–84%) | 53% (46–62%) | 63% (53–72%) | 68% (59–77%) | 59% (50–70%) | 79% (71–88%) |
Incidence rate in 2019, per 100,000 | 342 (285–403) | 168 (156–183) | 360 (312–414) | 595 (449–743) | 222 (187–265) | 287 (259–319) | 914 (782–1,055) | 354 (305–412) | 307 (271–352) | 230 (194–272) | 426 (382–474) |
Model estimates: All symptomatic TB | |||||||||||
Duration by P:N ratio, month | 8.7 (7.1–10.5) | 5.3 (4.0–6.7) | 11.8 ( 9.9–13.8) | 53.4 (43.6–64.1) | 20.6 (16.7–24.9) | 10.9 (9.4–12.4) | 10.9 (9.2–12.7) | 11.9 (9.4–14.6) | 13.3 (10.7–16.0) | 21.9 (18.6–25.6) | 9.7 (8.2–11.3) |
Time without care-seeking, month | 1.2 (0.6–1.9) | N.A. | 5.6 (4.6–6.8) | N.A. | 6.6 (4.8–8.6) | N.A. | 4.2 (3.3–5.2) | 4.2 (3.0–5.6) | 6.3 (4.9–7.8) | N.A. | 4.1 (3.3–5.1) |
Time bacteriologically positive, month | 8.0 (6.7– 9.6) | 4.8 (3.7–6.0) | 9.5 (8.2–11.1) | 21.6 (18.0–26.8) | 15.8 (13.2–19.0) | 8.2 (7.2–9.4) | 9.2 (7.9–10.6) | 10.4 (8.5–12.5) | 10.9 (9.1–13.0) | 14.2 (12.1–16.8) | 8.5 (7.3– 9.8) |
Case-detection ratio | 83% (77–89%) | 92% (87–96%) | 80% (73–86%) | 36% (29–44%) | 69% (59–79%) | 82% (76–88%) | 75% (69–81%) | 75% (67–82%) | 75% (67–82%) | 66% (57–75%) | 85% (78–91%) |
Incidence rate in 2019, per 100,000 | 270 (252–292) | 160 (154–169) | 309 (286–338) | 396 (315–482) | 203 (177–235) | 265 (247–285) | 643 (593–700) | 296 (269–329) | 277 (252–309) | 206 (181–235) | 397 (369–429) |
Other estimates/metrics | |||||||||||
Annual decline rate, % per year | 4.7% (4.4–5.0%) | 7.3% (7.1–7.5%) | 1.5% (1.3–1.6%) | − 8.0% (− 8.5% to − 7.5%) | 2.9% (2.6–3.2%) | 1.6% (1.5–1.7%) | − 8.3% (− 8.4% to − 8.2%) | − 2.4% (− 2.7% to − 2.2%) | − 1.3% (− 1.5% to − 1.1%) | 1.0% (0.7–1.4%) | 4.9% (4.7–5.1%) |
Asymptomatic phase over total duration, % | 64% (58–69%) | 47% (39–56%) | 48% (42–53%) | 40% (35–45%) | 27% (21–35%) | 37% (32–42%) | 59% (53–65%) | 45% (38–53%) | 32% (26–40%) | 31% (26–37%) | 37% (31–43%) |
Symptomatic TB without care-seeking, % | 15% (9–23%) | N.A. | 59% (51–67%) | N.A. | 42% (33–51%) | N.A. | 46% (38–54%) | 41% (31–50%) | 57% (48–67%) | N.A. | 48% (40–56%) |
Self-cure before case-detection | 32% (20–42%) | 14% (8–21%) | 27% (16–36%) | 50% (35–61%) | 30% (19–41%) | 20% (12–28%) | 32% (20–42%) | 27% (17–37%) | 23% (14–33%) | 30% (19–41%) | 20% (12–28%) |
Deaths before case-detection | 7% (6–9%) | 3% (2–4%) | 6% (5–7%) | 19% (15–26%) | 10% (8–12%) | 6% (5–7%) | 6% (5–7%) | 8% (6–10%) | 8% (6–9%) | 12% (10–14%) | 5% (4–6%) |